Last Updated: August 9, 2026

Claims for Patent: 11,045,558

✉ Email this page to a colleague

Summary for Patent: 11,045,558

Title:	RPGR gene therapy for retinitis pigmentosa
Abstract:	Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
Inventor(s):	Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin ALI
Assignee:	UCL Business Ltd , Massachusetts Eye and Ear , US Department of Health and Human Services
Application Number:	US16/436,521

Details for Patent 11,045,558

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009	⤷ Start Trial	2039-06-10
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	April 01, 2011	⤷ Start Trial	2039-06-10
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	August 20, 2020	⤷ Start Trial	2039-06-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,045,558

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016014353	⤷ Start Trial
United States of America	10314924	⤷ Start Trial
United States of America	2017216454	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.